Table 2. Alterations detected in Gastric cancer (GC) patients (n=22).
| Patient | SNV | Allele Frequency |
Validation (Sequencing) | CNA | Validation (RT-PCR) | Fusion |
|---|---|---|---|---|---|---|
| G1 | ND | |||||
| G2 | ND | ERRB2 (CN=5.29) MYC (CN=8.5) |
Yes | |||
| G3 | ND | |||||
| G4 | ND | CDK6 (CN=56.13) ERBB2 (CN=39.92) CCND1 (CN=7) |
Yes | |||
| G5 | KRAS-G12V | 21% | Sanger | N.E. | ||
| G6 | ND | CCND1 (CN=4.88) | Yes | |||
| G7 | ND | |||||
| G8 | ND | N.E. | ||||
| G9 | KRAS-G12D | 29% | Sanger | |||
| G10 | PIK3CA-E546R MAP2K1-L57T |
8% 5% |
Sanger * |
|||
| G11 | PIK3CA-E545L | 6% | ||||
| G12 | ND | |||||
| G13 | PIK3CA-M1043I ERBB2-R896C JAK3-R657G |
18% 12% 5% |
* | CCND1 (CN=6.5) MYC (CN=6.5) |
Yes | |
| G14 | ND | N.E. | ||||
| G15 | ND | ERBB2 (CN=10.62) | Yes | |||
| G16 | ND | |||||
| G17 | ND | N.E. | ||||
| G18 | ND | |||||
| G19 | EGFR-A289D ERBB2-R896C |
9% 18% |
||||
| G20 | PIK3CA-H1047R PIK3CA-H1048Y JAK3-R657G |
24% 58% 4% |
* |
|||
| G21 | PIK3CA-E547K KIT-D816N SMO-R290H ERBB3-E332K |
62% 2% 100% 80% |
Sanger * Sanger |
N.E. | ||
| G22 | NRAS-A146T NRAS-G61L KRAS-G13S |
5% 42% 13% |
Sanger | N.E. |
N.E. – Non Evaluable.
* SNV not confirmed Sanger sequencing.